Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.

Lilly sues online vendors, medical spa over copycat weight-loss drugs

Eli Lilly has triggered multiple Buy signals, including Timing, SAR, and Fundamental, with a 12-month target of ~$1,150. Technical indicators like Full Stochastic, Chaikin money flow, and ADX Demand signal show bullish trends and outperformance versus the Index. Despite strong Growth, Momentum, and Profitability scores, poor Valuation and Revision scores make LLY risky, leading to potential selling on good news.

Eli Lilly Buy On Weakness Signal (Technical Analysis)

Eli Lilly just secured a huge win, and it's not related to the weight loss industry.

1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now

Advanced Micro Devices

Builders FirstSource

These hot growth stocks may not be running out of steam just yet.

Investing $10,000 in Each of These 3 Stocks 10 Years Ago Would Have Made You $1.1 Million

Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.

Lilly Loses Around $14B This Week: How to Play LLY Stock

Sarepta Therapeutics

These innovative drugmakers have potential catalysts ahead.

2 High-Flying Growth Stocks With Massive Upside Potential

Eli Lilly is investing billions into new research and manufacturing capabilities.

This is Huge News For Eli Lilly Investors

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon

INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Lilly confirms date and conference call for third-quarter 2024 financial results announcement

Lilly is staying ahead of the technology curve instead of falling behind.

This Artificial Intelligence Move Is One New Reason to Buy Eli Lilly Stock in 2024

Results from Lilly's "Urgent Conversations" survey reinforce the work by the Crohn's & Colitis Foundation of America, including the "We Can't Wait" mobile bathroom finder app INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company (NYSE: LLY), found that over half (60%) of the general population struggle to find a public restroom, a challenge that is even more pronounced (84%) for people with ulcerative colitis (UC).1 This survey, of 1,800 U.S. adults, including 200 people with moderately to severely active UC, assessed the availability and accessibility of public restrooms. UC is a chronic, inflammatory disease that affects the colon and rectum of the gastrointestinal tract and is associated with increased stool frequency, rectal bleeding and bowel urgency.

Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies

Novo Nordisk

These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.

Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?

Lilly has invested billions of dollars to ramp up production capacity.

Should Eli Lilly Investors Worry About This Unexpected FDA Move?

The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.

FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List

Eli Lilly, the US pharmaceutical giant behind weight-loss drugs like Zepbound and Mounjaro, has announced a strategic partnership with the UK government to tackle significant health challenges, particularly obesity.

Eli Lilly to invest $364M in UK trial linking obesity drug to employment

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with weight-loss treatment giant, Eli Lilly. The U.S. pharmaceutical company and creator of blockbuster obesity injection Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain's significant health challenges.

Eli Lilly to trial use of weight loss drugs to combat unemployment in UK

Hims & Hers Health

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Pfizer

These two stocks will appeal to very different types of investors at the moment.

Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?

Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyond endoscopy, setting a new potential standard for the evaluation of therapeutic response INDIANAPOLIS , Oct. 14, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. VIVID-1 is the first Phase 3 study for any approved or investigational treatment in Crohn's disease to report histologic and combined histologic-endoscopic outcomes that were evaluated using a systematic assessment of five bowel segments (four colonic and one ileal) and strict definitions consistent with the recently published European Crohn's and Colitis (ECCO) position statement on mucosal histopathology.

Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease

Vertex Pharmaceuticals

These stocks look like slam-dunk picks for growth investors.

3 No-Brainer Growth Stocks to Buy in October

In a year and a half, Eli Lilly NYSE: LLY has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top

Chipotle

These industry leaders still look like top-notch buys.

Got $500? 2 Magnificent Growth Stocks to Buy and Hold Forever

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

FDA to reconsider decision barring compounded versions of Lilly weight loss drug

Eli Lilly stock has jumped 200% over the past two years.

News for Eli Lilly Stock (LLY)